Results Presented at the Heart Rhythm Society Meeting in
Boston, July 30, 2021
CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ - MindMics, Inc.
reported results from the clinical trial of revolutionary earbuds
that make use of a new technology -- in-ear infrasonic
hemodynography (IH) - for the monitoring of cardiac arrhythmias,
resulting in insights beyond those that have been possible with
state-of-the-art ECG monitoring. These results were presented
at the Heart Rhythm Society meeting in Boston, July 30,
2021.
Detailed Description of Clinical Trial and Results
The
clinical trial for recruiting atrial fibrillation (AF) patients was
approved by the institutional review board of The University of South Carolina School of Medicine.
Sinus Rhythm (SR) subjects were recruited in a separate study
approved by the New England institutional review board.
Synchronized MindMics In-ear Infrasonic Hemodynography (IH) data
and ECG were simultaneously recorded from 15 patients in AF and 15
in SR for 20 minutes. Recruited AF patients were between the ages
of 45 years and 90 years and showed a variety of arrhythmias.
Subjects for sinus rhythm were healthy individuals between the ages
of 25 and 73.
An oral presentation titled "MindMics: In-ear Infrasonic
Hemodynography For Cardiac Arrhythmia Assessment Beyond
ECG" was given at the Heart Rhythm Society 2021 Annual
Meeting: Bringing the World of EP (Electrophysiology) Together on
July 28-31. Key reported results
include:
- MindMics In-ear Infrasonic Hemodynography (IH) accurately
measures Interbeat intervals for diverse cardiac rhythms and
heart rates with an accuracy identical to ECG (R=0.99).
- Additionally, IH provides insights on associated hemodynamics
not accessible with ECG.
- The combination of precise determination of interbeat intervals
and hemodynamics offers a unique source of robust data to develop
algorithms for passive arrhythmia detection beyond the capabilities
of gold standard ECG applicable to a broad population. This can
also allow everyday users to improve their health and wellness with
beat-to-beat biofeedback with precision that does not exist in the
market today.
This confirms that the MindMics technology can offer a more
accurate measurement in many use cases where digital health is
taking the
lead.
"I would like to thank Dr. Francis
Roosevelt Gilliam III and his colleagues at Palmetto Health
USC Medical for designing and successfully completing this trial
study despite the COVID-19 pandemic. Cardiac rhythms are an
indicator of conditions ranging from stress to fatal health
complications that can lead to stroke. MindMics proprietary
technology embedded into earbuds has the potential to allow for
precision monitoring that could be available to everyone in a
wearable form. The results of this study support this potential,"
said Anna Barnacka, Ph.D., President and CEO of MindMics. "We are
particularly pleased that MindMics can measure the time between
heartbeats just as well as the gold standard ECG - even for heart
rhythms as complex as atrial fibrillation. We are also thrilled
that the story does not end there, as the data reveals that, in
addition, MindMics earbuds provide a more comprehensive view on
every heartbeat by showing insights on associated hemodynamics not
observable with an ECG. We believe that MindMics is a unique
next-generation health-and-wellness technology: real-time
medical-grade bio tracking delivered in an earbud." Charles R. Bridges, M.D., Sc.D., Chief Medical
Advisor of MindMics commented: "MindMics earbuds are positioned
equidistant from the heart and the brain allowing unparalleled,
precise and critical data to assess the functioning of both organs
in asymptomatic subjects and insights unavailable using any other
wearable technology on earth".
Note: The use of MindMics for cardiac arrhythmias is
investigational. The safety and effectiveness for this purpose has
not been reviewed by the United States Food and Drug Administration
(FDA).
About Cardiac Arrhythmias
Heart rhythm problems
(heart/cardiac arrhythmias) occur when the electrical impulses that
coordinate heartbeats don't work properly, causing the heart to
beat too fast, too slow or irregularly. Many heart arrhythmias are
harmless. However, if they are highly irregular or result from a
weak or damaged heart, arrhythmias can cause severe and potentially
fatal complications. There are several types of arrhythmia. The
most prevalent clinical arrhythmia is atrial fibrillation (AF or
AFib), which is projected to affect about 12.1 million Americans by
20301 and has been associated with increased risks for
stroke, hospitalization and early death. In many patients, AF is
not detected until the occurrence of a serious complication, such
as a stroke. Early detection and treatment of AF can be
critical. In general, heart failure and diseases are some of the
top causes of death.
About MindMics
MindMics is a technology start-up
focused on delivering actionable health monitoring for all.
Invented by Harvard-Smithsonian astrophysicist Dr Anna Barnacka, MindMics succeeds where
traditional wearable biofeedback devices fall short.
Delivered through earbuds similar to what millions of people
wear every day, MindMics uses intravascular sound waves (<20Hz)
in the ear canal to capture clinical-grade, high-definition
heartbeat information (the time between beats, similar to what an
ECG measures) and additional cardiac functions. This provides a
more complete picture of your working heart.
The global MindMics team brings deep expertise in
data science and product development to enhance the lives of
millions searching for a better way to improve their health and
realize their full potential.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmics-announces-results-from-a-clinical-trial-of-revolutionary-earbuds-technology----in-ear-infrasonic-hemodynography---to-achieve-cardiac-arrhythmia-assessment-beyond-that-of-ecg-301345736.html
SOURCE MindMics Inc.
